MedTrace Logo

Neuroprotective Effect of Dexomitomidine

NCT05487742 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-08-04

No results posted yet for this study

Summary

patient wih mild to moderate traumatic brain injury in ICU will be randomisly distributed into two groups Group I (control group): Patients of this group receive placebo infusion for 72 hours. Group II (DEX group): Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour Patient demographics, including age, sex, weight, primary diagnosis, Acute Physiology and Chronic Health Evaluation (APACHE) II score and postresuscitation Glasgow Coma Scale (GCS) score will be collected. CBF will be measured at pre-sedation and after cessation of sedation (dexmedetomidine administration). The CMRe and CMRe/CBF will also be calculated. Measurements of blood gas analysis and haemodynamic parameters \[systolic blood pressure (SBP), diastolic blood pressure (DBP), MAP and heart rate (HR)\] will be collected at pre-sedation and after cessation of sedation (dexmedetomidine administration).

Conditions

  • Dexmedetomidine Neuroprotective Effect in Traumatic Brain Injury

Interventions

DRUG

Dexmedetomidine

dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient

DRUG

placebo salin infusion

salin infused as aplacebo for 72 hours

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-04
Primary Completion
2022-12-31
Completion
2023-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05487742 on ClinicalTrials.gov